| Krystal Del Mar Ortiz-diaz, MD | |
|
Hospital Pavia Arecibo, Carr 129 Km 1.0 Ave San Luis, Arecibo, PR 00613 | |
| (787) 650-7272 | |
| Not Available |
| Full Name | Krystal Del Mar Ortiz-diaz |
|---|---|
| Gender | Female |
| Speciality | Surgery |
| Location | Hospital Pavia Arecibo, Arecibo, Puerto Rico |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093261745 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208600000X | Surgery | 22317 (Puerto Rico) | Primary |
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992737217 PECOS PAC ID: 3678469962 Enrollment ID: O20041228000034 |
News Archive
New findings from the University of Birmingham show that patients with chronic kidney disease patients and periodontitis (severe gum disease) have a higher mortality rate than those with chronic kidney disease alone.
Virginia Mason and Vera Whole Health today announced a strategic collaboration that brings Virginia Mason's clinical best practices to Vera Whole Health's employer-funded primary care clinics.
A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells.
Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for the generic version of Allegra-D® (Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release) 60mg/120mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Krystal Del Mar Ortiz-diaz, MD T15 Calle 19, Ext. Caguax, Caguas, PR 00725-3341 Ph: () - | Krystal Del Mar Ortiz-diaz, MD Hospital Pavia Arecibo, Carr 129 Km 1.0 Ave San Luis, Arecibo, PR 00613 Ph: (787) 650-7272 |
News Archive
New findings from the University of Birmingham show that patients with chronic kidney disease patients and periodontitis (severe gum disease) have a higher mortality rate than those with chronic kidney disease alone.
Virginia Mason and Vera Whole Health today announced a strategic collaboration that brings Virginia Mason's clinical best practices to Vera Whole Health's employer-funded primary care clinics.
A new international study co-led by Cleveland Clinic has identified a new drug target for treating glioblastoma. This target is part of a never-before defined cellular pathway found to contribute to the spread and proliferation of a dangerous subset of cancer cells, called glioma stem cells.
Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for the generic version of Allegra-D® (Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release) 60mg/120mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.
NeuroSigma, Inc., a California-based life sciences company focused on commercialization of its non-invasive Monarch eTNS System for the treatment of neurological and neuropsychiatric disorders, today announced that the U.S. National Institutes of Health (NIH) has awarded UCLA a grant that funds a Phase II 90-subject pediatric clinical trial at the University of California, Los Angeles focused on the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with NeuroSigma's external trigeminal nerve stimulation (eTNS) System.
› Verified 4 days ago
Victor E Vivoni, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Condominio Profesional Arecibo Medical Center, Suite 203 Carr #2 Km 80.1, Arecibo, PR 00614 Phone: 787-878-3397 Fax: 787-880-4104 | |
Marcos Devarie Hornedo, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Metropolitan Office Building 153 Calle Jose De Diego, Arecibo, PR 00612 Phone: 787-650-1030 | |
Luis A. Rodriguez-escola, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: Km 1 Pr-129, Hospital Pavia Arecibo, Arecibo, PR 00614 Phone: 787-300-2000 | |
Edwin I Soler, MD Surgery Medicare: Accepting Medicare Assignments Practice Location: Ave San Luis #622 Carr 129, Arecibo, PR 00612 Phone: 787-817-1269 Fax: 787-817-1269 | |
Guillermo Rivera Colon, M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: Carr 129 Km 1.1 Hospital Pavia Arecibo, Instituto De Cirugia Del Norte, Arecibo, PR 00613 Phone: 787-650-7272 Fax: 787-650-7269 | |
Dr. Emilio Eugenio Ramos Escoda, M.D Surgery Medicare: Not Enrolled in Medicare Practice Location: Street #129, Hospital Metropolitano Dr. Cayetano Coll Y Toste, Arecibo, PR 00612 Phone: 787-650-7272 Fax: 787-881-7598 |